- Guide to PHARMACOLOGY
Synonyms: AMG-827 | AMG827 | Kyntheum® | Lumicef® | Siliq®
brodalumab is an approved drug (Japan (2016), FDA (2017), EMA (2017))
Compound class: Antibody
Comment: Brodalumab is a human monoclonal antibody designed for the treatment of inflammatory diseases. It targets the interleukin 17 receptor A (IL17RA).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|Brodalumab was first approved in Japan (2016), and by the US FDA for plaque psoriasis the following year. Regulatory decisions are pending elsewhere. Clinical trials for the treatment of psoriatic arthritis (Phase 2I), moderate to severe plaque psoriasis (Phase 2I) and asthma (Phase 2) are ongoing. Encouraging results from a Phase 2 study have been reported .|
|Mechanism Of Action and Pharmacodynamic Effects|
|The IL-17 pathway is an established driver of psoriasis pathogenesis [1-3]. Brodalumab is an anti-IL17RA monoclonal antibody. Competitive inhibition of IL-17RA by brodalumab in psoriatic skin leads to rapid dose-dependent transcriptomal normalisation, ie genes up-regulated in psoraisis are returned to normal levels of transcription. This is accompanied by decreased keratinocyte hyperplasia and leukocyte infiltration, which are effects indicating a positive clinical response .|